Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Tyme Technologies Fell 35% on Friday

By Brian Orelli, PhD - Updated Apr 20, 2019 at 9:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The devil is in the clinical-trial details.

What happened

Shares of Tyme Technologies (TYME 1.10%) fell 35% on Friday after the biotech released data from a small phase 2 study of its oncology drug SM-88 in patients with advanced pancreatic cancer. The data was scheduled to be presented at the American Society of Clinical Oncology's 2019 Gastrointestinal Cancers Symposium today.

So what

The headline of the press release sounds great, noting that the drug "improves survival" -- but there wasn't a control group in this midstage trial. All the patients got the drug, and Tyme is just comparing the survival data to historical controls.

Specifically, the company notes that 79% of the 14 third-line patients in the trial -- those who had failed two prior therapies -- were alive after a median follow-up of 4.7 months, which is more than double the two-month median survival based on a retrospective analysis of third-line patients in 19 historical trials.

The problem with historical controls is that it's really hard to know if the 14 patients have the same characteristics as the patients who were in the previous clinical trials. And even if the patients were fairly similar, the history of best standard of care has generally improved over time, so historical controls have typically gotten better for most types of cancer.

Doctor showing a report to a patient in a hospital bed

Image source: Getty Images.

The company notes that eight of the 17 evaluable patients -- which includes some second-line and fourth-line or later patients -- had "stable disease or better." But when you go to the slides of the presentation for more details, it shows that only two of those patients had an actual response at their target lesion (and a partial response at that). The other six had stable disease. And the definition of stable disease is actually pretty broad -- three of the six had tumors that grew after two months.

Tyme argues that response rate in pancreatic cancer isn't a good indicator of survival because there's substantial scar tissue in the tumor, which will still show up on a scan, even if the drug is working.

To make matters worse, the poster on the company's website initially had the wrong graph of responses that included extra patients. Tyme said in an SEC statement that the company changed the figure because it included scans of patients who weren't at two months. It appears to be an honest mistake, but investors may be questioning whether there's more to it than that.

Now what

This year, Tyme plans to advance SM-88 into a clinical trial designed to get the drug approved for third-line pancreatic cancer. Presumably, the Food and Drug Administration will require that study to have a control arm comparing SM-88 to either placebo or perhaps physicians' choice, as there's no standard of care for late-line patients.

Based on the small number of patients and lack of responses in the data released today, it's hard to know whether the drug is actually working well enough to see an increase in survival in a controlled clinical trial.

Check out all our earnings call transcripts.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tyme Technologies, Inc. Stock Quote
Tyme Technologies, Inc.
$0.33 (1.10%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.